VALOR-CKD:Veverimer 延缓慢性肾脏病合并代谢性酸中毒进展的多中心随机双盲安慰剂对照试验
VALOR-CKD 试验纳入 1480 例慢性肾脏病(CKD)合并代谢性酸中毒患者,随机接受 veverimer 或安慰剂治疗。结果显示 veverimer 未延缓 CKD 进展(主要终点事件风险比 0.99,95%CI 0.8–1.2,P=0.90),且药物与安慰剂组血清碳酸氢盐差异仅约 1 mEq/L。Veverimer 安全耐受良好。
要点
- 在 CKD 合并代谢性酸中毒患者中,veverimer 未延缓 CKD 进展。
- 药物与安慰剂组血清碳酸氢盐差异仅约 1 mEq/L,可能限制假说验证。
- Veverimer 安全性和耐受性良好,严重及总体不良事件发生率无差异。
核心结论
- 在 CKD 合并代谢性酸中毒患者中,veverimer 治疗未延缓 CKD 进展。
- 药物与安慰剂组血清碳酸氢盐分离度低于预期,可能妨碍假说检验。
- Veverimer 安全且耐受良好,严重及总体不良事件发生率两组无差异。
研究设计与样本
- VALOR-CKD 为 3 期多中心随机双盲安慰剂对照试验,纳入 1480 例 CKD 合并代谢性酸中毒患者,来自 35 个国家 320 个中心。
- 入选标准为 eGFR 20–40 ml/min/1.73 m² 且血清碳酸氢盐 12–20 mEq/L。
- 患者随机接受 veverimer 或安慰剂,主要终点为 CKD 进展复合终点(ESKD、eGFR 较基线持续下降≥40% 或肾衰竭死亡)。
主要发现
- 基线平均 eGFR 为 29.2±6.3 ml/min/1.73 m²,血清碳酸氢盐为 17.5±1.4 mEq/L,活性治疗导入后升至 23.4±2.0 mEq/L。
- 随机撤药后第 3 个月,veverimer 组和安慰剂组平均血清碳酸氢盐分别为 22.0±3.0 mEq/L 和 20.9±3.3 mEq/L,约 1 mEq/L 差异在前 24 个月保持稳定。
- 主要终点事件在 veverimer 组和安慰剂组分别发生 149/741 和 148/739 例(风险比 0.99;95%CI 0.8–1.2;P=0.90)。
- 严重不良事件和总体不良事件发生率两组无差异。
关键数值与推荐
- 主要终点事件风险比 0.99(95%CI 0.8–1.2;P=0.90),veverimer 组 149/741 例,安慰剂组 148/739 例。
- 第 3 个月血清碳酸氢盐 veverimer 组 22.0±3.0 mEq/L,安慰剂组 20.9±3.3 mEq/L,差异约 1 mEq/L 且前 24 个月稳定。
临床怎么用
- 对于 CKD 合并代谢性酸中毒患者,veverimer 不应以延缓 CKD 进展为目的使用。
- 该试验中碳酸氢盐分离度仅约 1 mEq/L,解读阴性结果需考虑这一因素。
局限性
- 药物与安慰剂组血清碳酸氢盐差异低于预期(约 1 mEq/L),可能妨碍假说检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Metabolic acidosis is a common complication of CKD and is associated with more rapid decline of kidney function, but well-powered controlled randomized trials testing the effect of treating metabolic acidosis on slowing CKD progression have not been conducted. The VALOR-CKD study randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or veverimer (a novel hydrochloric acid binder). The findings did not demonstrate the efficacy of veverimer in slowing CKD progression, but the difference in serum bicarbonate between placebo and drug arms was only approximately 1 mEq/L. Veverimer was safe and well tolerated. BACKGROUND: Metabolic acidosis is common in CKD, but whether its treatment slows CKD progression is unknown. Veverimer, a novel hydrochloric acid binder that removes acid from the gastrointestinal tract, leads to an increase in serum bicarbonate. METHODS: In a phase 3, double-blind, placebo-controlled trial, patients with CKD (eGFR of 20-40 ml/min per 1.73 m 2 ) and metabolic acidosis (serum bicarbonate of 12-20 mEq/L) from 35 countries were randomized to veverimer or placebo. The primary outcome was the composite end point of CKD progression, defined as the development of ESKD (kidney transplantation or maintenance dialysis), a sustained decline in eGFR of ≥40% from baseline, or death due to kidney failure. RESULTS: The mean (±SD) baseline eGFR was 29.2±6.3 ml/min per 1.73 m 2 , and serum bicarbonate was 17.5±1.4 mEq/L; this increased to 23.4±2.0 mEq/L after the active treatment run-in. After randomized withdrawal, the mean serum bicarbonate was 22.0±3.0 mEq/L and 20.9±3.3 mEq/L in the veverimer and placebo groups at month 3, and this approximately 1 mEq/L difference remained stable for the first 24 months. A primary end point event occurred in 149/741 and 148/739 patients in the veverimer and placebo groups, respectively (hazard ratio, 0.99; 95% confidence interval, 0.8 to 1.2; P = 0.90). Serious and overall adverse event incidence did not differ between the groups. CONCLUSIONS: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression. The lower than expected bicarbonate separation may have hindered the ability to test the hypothesis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: VALOR-CKD, NCT03710291 .
引用
- Tangri N, Mathur VS, Bushinsky DA, et al. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis. J Am Soc Nephrol. 2024. PMID: 38261535. doi:10.1681/ASN.0000000000000292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。